COVID-19

The rapid emergence of the novel Coronavirus Disease 2019 (COVID-19) pandemic spurred national concerns about the social determinants of health (SDOH) as risk factors for infection and their potential to negatively impact health outcomes.

This ASPE issue brief examines hesitancy among parents to vaccinate children ages 5-11 and 12-17 using data from the U.S. Census Bureau's Household Pulse Survey. Overall, a larger percent of parents with children aged 5-11 are hesitant to vaccinate their children (34 percent) than parents of children aged 12-17 (21 percent).

The National Health Interview Survey (NHIS) provides annual and quarterly data on health insurance coverage by insurance type, age, and income.

Anti-SARS-CoV-2 monoclonal antibodies are an effective treatment to prevent progression to severe COVID-19 or hospitalization in high-risk individuals. Despite the benefits offered by monoclonal antibody treatment, early reports indicated that these therapeutics were not being widely used.

This ASPE Research Report models the estimated reductions in COVID-19 cases, hospitalizations, and deaths associated with COVID-19 vaccination from December 2020 through July 2021. To download the Research Report, please download the PDF to the right under “Files”. To explore our dashboard that presents the Report’s results, please see below.

This research report examines changes in Medicare fee-for-service Part B visits and use of telehealth in 2020 during the COVID-19 public health emergency (PHE) by beneficiary characteristics, provider specialty, and location. The analysis found that Medicare in-person visits dropped while telehealth visits increased significantly at the start of the pandemic.

The purpose of this study is to identify associations between COVID-19 infections, hospitalizations, and deaths among Medicare fee-for-service (FFS) beneficiaries and the proportion of the population fully vaccinated at the county-level between January and May 2021.

As of September 13, 2021, three vaccines to prevent infection with SARS-CoV-2, the virus that causes COVID-19, are available in the United States. The Pfizer vaccine was granted full approval for use in individuals over the age of 16 by the U.S.

COVID-19 pandemic’s social restrictions have prompted a surge in the mental health needs of children of all ages. Nationwide 4.3 million children/adolescents have been diagnosed with COVID-19 as of August 2021, and many of them have returned to early childhood and school settings. Schools and early childhood programs have long been essential settings for delivery of mental health services.

This brief provides a high level overview of the impact of COVID-19 on the development, emotional and behavioral health, social, and economic well-being of children and youth (ages birth to 24).Related Products: